Global Live Cell Encapsulation Market Size, Share, and COVID-19 Impact Analysis, By Polymer Type (Natural Polymers and Synthetic Polymers), By Method (Microencapsulation, Macroencapsulation, and Nanoencapsulation), By Application (Drug Delivery and Cell Transplantation), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033.

Industry: Healthcare

RELEASE DATE Jul 2024
REPORT ID SI4663
PAGES 260
REPORT FORMAT PathSoft

Global Live Cell Encapsulation Market Insights Forecasts to 2033

  • The Global Live Cell Encapsulation Market Size was Valued at USD 225.10 Million in 2023
  • The Market Size is Growing at a CAGR of 3.52% from 2023 to 2033
  • The Worldwide Live Cell Encapsulation Market Size is Expected to Reach USD 318.06 Million by 2033
  • Asia Pacific is Expected to Grow the fastest during the forecast period.

 

Global Live Cell Encapsulation Market

Get more details on this report -

Request Free Sample PDF

 

The Global Live Cell Encapsulation Market Size is Anticipated to Exceed USD 318.06 Million by 2033, Growing at a CAGR of 3.52% from 2023 to 2033.

 

Market Overview

Live cell encapsulation is the technology used for the microencapsulation of live cells and tissues within the protective membrane. A physical barrier is imposed by the polymeric semipermeable membrane, prohibiting any direct contact between the confined cells and the membrane enclosing them. With its ability to deliver cells and cell-based therapies in a secure and controlled way, this technology has the potential to transform several fields of study and medicine. Controlled release of cells or bioactive compounds is one of the main benefits of live cell encapsulation. It is especially helpful in cell-based therapies, where the objective is to protect therapeutic cells from the body's immune system while delivering them to a particular portion of the body. Thus, one of the primary advantages of live cell encapsulation is its capacity to release cells or other bioactive chemicals under controlled circumstances. It is particularly useful in cell-based therapies, where the goal is to deliver therapeutic cells to a particular part of the body while protecting them from the host's immunological reaction. This related advantage will increase the need for live-cell encapsulation. Growth in cell therapy and regenerative medicine has created a growing market for live cell encapsulation. By improving the ability to survive and functionality of encapsulated cells, developments in microencapsulation techniques and biomaterials have transformed the field. Researchers searching for new therapeutic uses and methodologies are anticipated to drive market growth, particularly as the importance of customized medicine increases. Technology for live cell encapsulation has grown in significance to fulfill the growing need for specific therapeutics. The market has experienced growth due to the increasing investments made by public-private partnerships.

 

Report Coverage

This research report categorizes the market for the global live cell encapsulation market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global live cell encapsulation market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global live cell encapsulation market.

 

Global Live Cell Encapsulation Market Report Coverage

Report CoverageDetails
Base Year:2023
Market Size in 2023:USD 225.10 Million
Forecast Period:2023 - 2033
Forecast Period CAGR 2023 - 2033 :3.52%
2033 Value Projection:USD 318.06 Million
Historical Data for:2019-2022
No. of Pages:260
Tables, Charts & Figures:110
Segments covered:By Polymer Type, By Method, By Application, By Region
Companies covered:: AUSTRIANOVA, Merck KGaA, Sphere Fluidics Limited, ViaCyte, Blacktrace Holdings Ltd (Dolomite Microfluidics), BIO INX, Living Cell Technologies Limited, Sigilon Therapeutics, Isogen, Diatranz Otsuka Ltd., Sigilon TherapeuticsInc, MiKroCaps, Neurotech Holdings LLC, and Others
Pitfalls & Challenges:Covid 19 Impact Challanges, Future, Growth and Analysis

Get more details on this report -

Request Free Sample PDF
 

Driving Factors

Profitable market opportunities are anticipated as a result of the top companies' innovative product launches and technological advancements. Market expansion is probably going to be driven by more research initiatives aimed at demonstrating the therapeutic efficacy of the cell encapsulation process. Throughout the projection, the growing application in the development of treatments for major chronic diseases like diabetes, cancer, and autoimmune disorders will also support market expansion. A key driver of the industry is the advancement of encapsulating technology. Researchers are developing new methods to create capsules that are biocompatible and effective. Among the advancements are precise control over chemical exchange, capsules that promote cell viability, and targeted administration systems. Moreover, complex structures can be constructed and cell functionality enhanced through the use of 3D bioprinting and microfluidic technologies.

 

Restraining Factors

Several variables can contribute to the relatively high manufacturing cost of live cell encapsulation. Costly specialized tools and knowledge are needed for the manufacturing of the capsules or microspheres. Furthermore, the cells utilized in the encapsulation procedure are frequently fragile and need to be handled and processed carefully, which raises the production costs. The regulatory requirements necessary for ensuring the finished product's safety and efficacy also add to the expense of live cell encapsulation. This might entail thorough testing and validation, which could be costly and time-consuming.

 

Market Segmentation

The global live cell encapsulation market share is segmented into polymer type, method, and application.

 

  • The natural polymers segment dominates the market with the largest market share through the forecast period.

Based on the polymer type, the global live cell encapsulation market is segmented into natural polymers and synthetic polymers. Among these, the natural polymers segment dominates the market with the largest market share through the forecast period. Natural polymers are preferred as the key choice for encapsulation. Large molecular weight macromolecules found in nature called natural polymers are selected for their biodegradability, low toxicity, biocompatibility, renewability, and adaptability to change. Due to their natural origins microorganisms, animals, and plants, for instance, can interact with cells and tissues and exhibit characteristics that the body can relate to, so it does not perceive them as external entities. To encapsulate hydrophobic or hydrophilic active ingredients which might be in solid, liquid, or gaseous states for transportation and distribution to the necessary places, natural polymers like lipids, proteins, and polysaccharides have been used.

 

  • The nanoencapsulation segment is anticipated to grow at the fastest CAGR growth through the forecast period.

Based on the method, the global live cell encapsulation market is segmented into microencapsulation, macroencapsulation, and nanoencapsulation. Among these, the nanoencapsulation segment is anticipated to grow at the fastest CAGR growth through the forecast period. Since the size of the nanoparticle affects the distribution of encapsulated therapeutic/diagnostic agents, the science of nanoencapsulation is primarily used in the creation of efficient drug delivery systems. In comparison to other methods, nanoencapsulation has superior performance. It can enhance both passive and active targeting of bioactive molecules to the site of action, augment drug solubility, enhance bioavailability, and modulate or delay drug release. Thus, benefits related to nanoencapsulation are anticipated to boost market expansion.

 

  • The drug delivery segment accounted for the largest revenue share through the forecast period.

Based on the application, the global live cell encapsulation market is segmented into drug delivery and cell transplantation. Among these, the drug delivery segment accounted for the largest revenue share through the forecast period. Capsules, pills, and parenteral dosage forms are made using the live cell encapsulation technique to ensure efficient drug delivery. In many diseases with a progressive course, controlled drug administration holds enormous potential. The market is being driven by benefits such as increased therapeutic effects, decreased medication dosage, less cytotoxicity, better patient convenience, and increased compliance that come with regulated drug administration using live cell encapsulation. The growing use of cell encapsulation in medicine delivery offers operational advantages like improved results for patients, fewer side effects, and better effectiveness.

 

Regional Segment Analysis of the Global Live Cell Encapsulation Market

  • North America (U.S., Canada, Mexico) 
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Rest of APAC)
  • South America (Brazil and the Rest of South America) 
  • The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the global live cell encapsulation market over the predicted timeframe.

 

Global Live Cell Encapsulation Market

Get more details on this report -

Request Free Sample PDF

 

North America is projected to hold the largest share of the global live cell encapsulation market over the predicted timeframe. This significant portion can be attributed to government support, advantageous laws, and greater financing for private businesses. The region primarily focuses on drug discovery research, which drives industry growth. The area has seen more product penetration due to the presence of innovators and important operational players. and higher government and healthcare sector research and development, the increasing public-private investment in the live cell encapsulation industry in the U.S. and Canada will fuel market expansion.

 

Asia Pacific is expected to grow at the fastest CAGR growth of the global live cell encapsulation market during the forecast period. The biotechnology and pharmaceutical sectors of emerging economies like China and India are responsible for the immense expansion. Another factor contributing to this region's successful growth is the continuous support from the government for the advancement of the pharmaceutical industry in developing nations. Furthermore, the live cell encapsulation market in the region is anticipated to rise significantly due to going on research in the sectors of infectious disorders and cancer.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global live cell encapsulation market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

  • AUSTRIANOVA
  • Merck KGaA
  • Sphere Fluidics Limited
  • ViaCyte
  • Blacktrace Holdings Ltd (Dolomite Microfluidics)
  • BIO INX
  • Living Cell Technologies Limited
  • Sigilon Therapeutics
  • Isogen
  • Diatranz Otsuka Ltd.
  • Sigilon TherapeuticsInc
  • MiKroCaps
  • Neurotech Holdings LLC
  • Others

 

Key Target Audience

  • Market Players
  • Investors
  • End-users
  • Government Authorities 
  • Consulting And Research Firm
  • Venture capitalists
  • Value-Added Resellers (VARs)

 

Recent Developments

 

  • In March 2023, SG Austria (Austrianova) announced that Checkmate Capital Group, a multi-family investment and advisory group based in California, has made a preferred equity investment in SG Austria, the parent company of Austrianova. This investment helped the company to expand and grow.

 

  • In November 2022, BIO INX launched Hydrobio INX N400, the first commercially available bioresin enabling live cell encapsulation in healthcare 3D printing with Nanoscribe's two-photon polymerization technology. This strategy helped the company to expand its product portfolio and customer base.

 

  • In June 2020, Sernova Acquired Cellular Local Immune Protection Technology Accelerating the Expansion of its Regenerative Medicine Therapeutics Platform.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global live cell encapsulation market based on the below-mentioned segments: 

 

Global Live Cell Encapsulation Market, By Polymer Type

  • Natural Polymers
  • Synthetic Polymers

 

Global Live Cell Encapsulation Market, By Method

  • Microencapsulation
  • Macroencapsulation
  • Nanoencapsulation

 

Global Live Cell Encapsulation Market, By Application

  • Drug Delivery
  • Cell Transplantation

 

Global Live Cell Encapsulation Market, By Regional Analysis

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Qatar
    • South Africa
    • Rest of the Middle East & Africa

Frequently Asked Questions (FAQ)

  • 1. Which are the key companies that are currently operating within the market?
    AUSTRIANOVA, Merck KGaA, Sphere Fluidics Limited, ViaCyte, Blacktrace Holdings Ltd (Dolomite Microfluidics), BIO INX, Living Cell Technologies Limited, Sigilon Therapeutics, Isogen, Diatranz Otsuka Ltd., Sigilon Therapeutics Inc, MiKroCaps, Neurotech Holdings LLC, and Others.
  • 2. What is the size of the Global Live Cell Encapsulation Market?
    The Global Live Cell Encapsulation Market Size is Expected to Grow from USD 225.10 Million in 2023 to USD 318.06 Million by 2033, at a CAGR of 3.52% during the forecast period 2023-2033.
  • 3. Which region is holding the largest share of the market?
    North America is anticipated to hold the largest share of the global live cell encapsulation market over the predicted timeframe.

Need help to buy this report?

Inquiry Before Buy
We'll use cookies to improve and customize your experience if you continue to browse. Is it OK if we also use cookies to show you personalized ads?
Learn more and manage your cookies
Yes, Accept Cookies